Redcare Pharmacy Shares Continue to Plunge Amid Sustained Selling Pressure

The stock of Redcare Pharmacy remains trapped in a pronounced and persistent downtrend, showing few signs of finding a stable floor. Recent trading activity underscores the bearish sentiment, with the share price closing lower in eight out of the last ten sessions. This selling pressure has erased over 23% of the stock’s value in just the past fortnight.

Technical Indicators Flash Deeply Oversold Signals

From a technical perspective, the equity is now considered severely oversold. The 14-day Relative Strength Index (RSI) recently registered a reading of 16, falling well below the traditional oversold threshold of 30. The share price has sunk to a fresh 52-week low, trading approximately 77% below its annual peak of €136.50, which was recorded as recently as May 2025. The current price level also sits nearly 57% below its 200-day moving average, a gap that highlights the severity of the decline. The next notable technical resistance levels are seen at €32.49 and €51.05, both remaining far above present valuations.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Lack of Buyer Engagement Compounds Weakness

Market activity provides little encouragement for a near-term reversal. Trading volume offers a clear view of the diminished interest, with only 124,000 shares changing hands this past Friday—a drop of 20,000 from the previous session. Declining volume during a sustained price fall typically indicates that potential buyers are staying on the sidelines, awaiting a catalyst.

In the absence of new fundamental developments that could trigger a re-rating, the technical outlook remains decidedly negative. Investors are now likely looking toward the company’s first-quarter 2026 results, due for release in the coming months, for concrete signals regarding the underlying business performance. Until then, the path of least resistance appears to be downward.